How did cbdMD's revenue and expenses trend in Q1 2025?

**CBDMD's revenue and expenses in Q1 2025 showed positive trends with improved profitability.**

1. **Revenue Trend**: CBDMD reported a total net sales of $5.1 million for Q1 2025, which represents a 12% increase sequentially from the previous quarter, despite a 5% year-over-year decrease. This indicates a rebound in sales and a successful expansion of market reach.

|code|Ticker|Name|Date|Total Revenue|Total Expenses|Net Income|market_code|
|---|---|---|---|---|---|---|---|
|YCBD|YCBD.A|cbdMD|2024 Q2|4376518||-3010562|170|
|YCBD|YCBD.A|cbdMD|2024 Q3|5173878||459737|170|
|YCBD|YCBD.A|cbdMD|2024 Q4|4556366||-152799|170|
|YCBD|YCBD.A|cbdMD|2025 Q1|5113476||15095|170|

2. **Expense Trend**: The company's total expenses, particularly SG&A costs, decreased significantly. SDNA expenses, for instance, reduced from $4.6 million in the prior year to $3.4 million. This decrease reflects effective cost management strategies and a commitment to financial discipline.
3. **Profitability**: CBDMD achieved its first-ever positive net income of $15,000 in Q1 2025, compared to a loss of $977,000 in the same quarter of the previous year. Additionally, the company reported a positive non-GAAP adjusted EBITDA of $214,000, indicating improved financial health and operational efficiency.
4. **Debt Status**: CBDMD became debt-free, excluding ordinary liabilities and accrued dividends, which is a significant achievement that enhances financial flexibility and stability.

In conclusion, CBDMD's revenue showed a positive trend with an increase sequentially and a strong performance in its wholesale division. The company's expenses were effectively managed, leading to a significant improvement in profitability and a debt-free status, which are positive indicators for its financial health.